MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma

Study Overview
=================
Brief Summary
-----------------
The lymph nodes or masses,positron emission tomography/computed tomography (PET/CT) standardized uptake values(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*, f values and MRI volumes of lymphoma patients were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation. Long-term therapeutic effect indexes obtained in follow-up visits of patients such as Overall Survival(OS), Progression Free Survival (PFS) etc. were used to evaluate the diagnostic sensitivity and differences of MRI and PET/CT. The research could provide a new method of nonionizing radiation iconography for physicians to give appropriate treatments and predict prognosis.

Official Title
-----------------
Research on the Lymphoma Staging and Therapeutic Evaluation of 18F-FDG PET/CT Comparing With Whole Body MRI IVIM Functional Imaging

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Device: magnetic resonance imaging
* Device: positron emission tomography/computed tomography
* Radiation: fludeoxyglucose F 18


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by a reference pathologist. Patients who gave written informed consent were referred for DWI-MRI and 18F-FDG-PET/CT. Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging). Exclusion Criteria: Pregnancy, general contraindications to MRI, and therapeutic interventions between DWI-MRI and 18F-FDG-PET/CT were used.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lymphoma<br>The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation. | Device: magnetic resonance imaging<br>* MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.<br>* Other names: MRI;Device: positron emission tomography/computed tomography<br>* 18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.<br>* Other names: PET/CT;Radiation: fludeoxyglucose F 18<br>* Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.<br>* Other names: FDG;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 18F-FDG uptake in lymphomas with PET/CT | Different 18F-FDG uptake values in lymphoma tissue (e.g. SUVmax, SUVmean, binding potential) will be measured and correlated with immunohistochemically determined somatostatin receptor status, lymphoma aggressiveness and tissue biomarkers | Within 30 days prior to start of chemotherapy | 
| Agreement between DWI-MRI and 18F-FDG PET/CT at diagnosis | Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT at diagnosis. | Within 30 days prior to start of chemotherapy | 
| Agreement between DWI-MRI and 18F-FDG PET/CT in follow-up examinations | Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT after completion of chemotherapy for treatment response assessment | 2 weeks after the 4th cycle of chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival |  | 12 months | 
| Progression Free Survival |  | 6 months |